Advertisement
New Zealand markets closed
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NZD/USD

    0.6133
    -0.0038 (-0.62%)
     
  • NZD/EUR

    0.5730
    -0.0011 (-0.19%)
     
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • OIL

    78.90
    +0.28 (+0.36%)
     
  • GOLD

    2,344.60
    +26.60 (+1.15%)
     
  • NASDAQ

    19,576.92
    +111.74 (+0.57%)
     
  • FTSE

    8,156.34
    -7.33 (-0.09%)
     
  • Dow Jones

    38,647.10
    -65.11 (-0.17%)
     
  • DAX

    18,037.78
    -227.90 (-1.25%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • NZD/JPY

    96.3850
    -0.4350 (-0.45%)
     

Can This New Drug Boost Pfizer's Stock?

Can This New Drug Boost Pfizer's Stock?

Pfizer's (NYSE: PFE) nasal spray Zavzpret was given the green light by the Food and Drug Administration earlier this month to treat patients with acute migraine. With this approval, the pharmaceutical company now has an acute migraine treatment in nasal spray form to complement the oral treatment in its portfolio, Nurtec ODT. What could Zavzpret contribute to Pfizer's top line?